Screener
Kymera Therapeutics KYMR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Kymera Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 7:15 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193967
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of property and equipment, net | (434) | (467) |
| Purchases of investments | (276,266) | (83,656) |
| Maturities of investments | 133,860 | 132,738 |
| Net cash (used in) provided by investing activities | $(142,840) | $48,615 |
| Financing activities | ||
| Proceeds from stock option exercises | 19,194 | 535 |
| Payments on finance leases | (425) | (277) |
| Net cash provided by financing activities | $18,769 | $258 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's investing cash flow?
- Kymera Therapeutics (KYMR) reported investing cash flow of -$142.84M in Q1 2026.
- How has Kymera Therapeutics's investing cash flow changed year-over-year?
- Kymera Therapeutics's investing cash flow decreased by 393.8% year-over-year, from $48.62M to -$142.84M.
- What is the long-term trend for Kymera Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Kymera Therapeutics's investing cash flow has grown at a 128.5% compound annual growth rate (CAGR), from -$99.84M to -$521.06M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Kymera Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude